^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TRS003 (bevacizumab biosimilar)
i
Other names: TRS-003, TRS003
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Zhejiang Teruisi Biopharma
Drug class:
VEGF-A inhibitor
Related drugs:
over2years
A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC (clinicaltrials.gov)
P3, N=126, Not yet recruiting, Zhejiang Teruisi Pharmaceutical Inc.
New P3 trial
|
BRAF (B-raf proto-oncogene)
|
BRAF mutation
|
Avastin (bevacizumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • TRS003 (bevacizumab biosimilar)
4years
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (clinicaltrials.gov)
P3, N=608, Recruiting, Zhejiang Teruisi Pharmaceutical Inc. | Not yet recruiting --> Recruiting
Clinical • Enrollment open
|
ALK (Anaplastic lymphoma kinase)
|
Avastin (bevacizumab) • carboplatin • paclitaxel • TRS003 (bevacizumab biosimilar)
over4years
A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC (clinicaltrials.gov)
P3, N=608, Not yet recruiting, Zhejiang Teruisi Pharmaceutical Inc.
Clinical • New P3 trial
|
ALK (Anaplastic lymphoma kinase)
|
Avastin (bevacizumab) • carboplatin • paclitaxel • TRS003 (bevacizumab biosimilar)
Share via
